WO2008014035A3 - Modulation of nkg2d and method for treating or preventing solid organ allograft rejection - Google Patents

Modulation of nkg2d and method for treating or preventing solid organ allograft rejection Download PDF

Info

Publication number
WO2008014035A3
WO2008014035A3 PCT/US2007/068348 US2007068348W WO2008014035A3 WO 2008014035 A3 WO2008014035 A3 WO 2008014035A3 US 2007068348 W US2007068348 W US 2007068348W WO 2008014035 A3 WO2008014035 A3 WO 2008014035A3
Authority
WO
WIPO (PCT)
Prior art keywords
nkg2d
treating
cells
allograft rejection
solid organ
Prior art date
Application number
PCT/US2007/068348
Other languages
French (fr)
Other versions
WO2008014035A2 (en
Inventor
Jody L Baron
Sang-Mo Kang
Lewis L Lanier
Original Assignee
Univ California
Jody L Baron
Sang-Mo Kang
Lewis L Lanier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Jody L Baron, Sang-Mo Kang, Lewis L Lanier filed Critical Univ California
Publication of WO2008014035A2 publication Critical patent/WO2008014035A2/en
Publication of WO2008014035A3 publication Critical patent/WO2008014035A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • C12N2310/111Antisense spanning the whole gene, or a large part of it
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/50Physical structure
    • C12N2310/53Physical structure partially self-complementary or closed

Abstract

The present invention relates to methods and compositions for treating and/or preventing autoimmune and/or inflammatory disease. In particular, the present invention provides therapeutics for impairing the expansion and function of autoreactive T cells, NK cells and/or NKT cells, by modulating NKG2D. The present application also relates to method for treating or preventing solid organ allograft rejection, the method comprising administering an agent that reduces ligand-induced NKG2D activation of cells (such as an antibody that binds NKG2D) and an inhibitor of lymphocyte co-stimulation to a subject in need thereof (such as CTLA4-Ig or LEA29Y)
PCT/US2007/068348 2006-07-25 2007-05-07 Modulation of nkg2d and method for treating or preventing solid organ allograft rejection WO2008014035A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83338306P 2006-07-25 2006-07-25
US60/833,383 2006-07-25

Publications (2)

Publication Number Publication Date
WO2008014035A2 WO2008014035A2 (en) 2008-01-31
WO2008014035A3 true WO2008014035A3 (en) 2008-04-03

Family

ID=38969958

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/068348 WO2008014035A2 (en) 2006-07-25 2007-05-07 Modulation of nkg2d and method for treating or preventing solid organ allograft rejection

Country Status (1)

Country Link
WO (1) WO2008014035A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2769409A1 (en) * 2009-08-17 2011-02-24 The Penn State Research Foundation Use of nkg2d inhibitors for treating cardiovascular and metabolic diseases, such as type 2 diabetes
US20140248289A1 (en) * 2011-08-26 2014-09-04 University Of Cincinnati Methods and Compositions for the Treatment of Respiratory Conditions Via NKG2D Inhibition

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002094202A2 (en) * 2001-05-23 2002-11-28 Bristol-Myers Squibb Company Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules
WO2005097160A2 (en) * 2004-04-05 2005-10-20 The Regents Of The University Of California Modulation of nkg2d
WO2006108035A1 (en) * 2005-04-06 2006-10-12 Bristol-Myers Squibb Company Methods for treating immune disorders associated with graft transplantation with soluble ctla4 mutant molecules

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002094202A2 (en) * 2001-05-23 2002-11-28 Bristol-Myers Squibb Company Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules
WO2005097160A2 (en) * 2004-04-05 2005-10-20 The Regents Of The University Of California Modulation of nkg2d
WO2006108035A1 (en) * 2005-04-06 2006-10-12 Bristol-Myers Squibb Company Methods for treating immune disorders associated with graft transplantation with soluble ctla4 mutant molecules

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
ADAMS A B ET AL: "CALCINEURIN INHIBITOR-FREE CD28 BLOCKADE-BASED PROTOCOL PROTECTS ALLOGENEIC ISLETS IN NONHUMAN PRIMATES", DIABETES, NEW YORK, NY, US, vol. 51, no. 2, February 2002 (2002-02-01), pages 265 - 270, XP008054843, ISSN: 0012-1797 *
ADAMS A B ET AL: "Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 174, no. 1, 1 January 2005 (2005-01-01), pages 542 - 550, XP002393472, ISSN: 0022-1767 *
HANCOCK W W ET AL: "Chemokines and their receptors as markers of allograft rejection and targets for immunosuppression", CURRENT OPINION IN IMMUNOLOGY, ELSEVIER, OXFORD, GB, vol. 15, no. 5, October 2003 (2003-10-01), pages 479 - 486, XP004457002, ISSN: 0952-7915 *
HATTORI RYOHEI ET AL: "[Renal transplantation]", NIPPON RINSHO. JAPANESE JOURNAL OF CLINICAL MEDICINE NOV 2005, vol. 63, no. 11, November 2005 (2005-11-01), pages 1950 - 1955, XP009095381, ISSN: 0047-1852 *
LARSEN C P ET AL: "Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties", AMERICAN JOURNAL OF TRANSPLANTATION, BLACKWELL MUNKSGAARD,, DK, vol. 5, no. 3, March 2005 (2005-03-01), pages 443 - 453, XP002393471, ISSN: 1600-6135 *
LI ET AL: "CTLA4-Ig-Based Conditioning Regimen to Induce Tolerance to Cardiac Allografts", JOURNAL OF SURGICAL RESEARCH, ACADEMIC PRESS INC., SAN DIEGO, CA, US, vol. 136, no. 2, 15 November 2006 (2006-11-15), pages 238 - 246, XP005741054, ISSN: 0022-4804 *
MAIER STEFAN ET AL: "Inhibition of natural killer cells results in acceptance of cardiac allografts in CD28-/- mice", NATURE MEDICINE, vol. 7, no. 5, May 2001 (2001-05-01), pages 557 - 562, XP002467594, ISSN: 1078-8956 *
MCNERNEY M E ET AL: "Role of natural killer cell subsets in cardiac allograft rejection.", AMERICAN JOURNAL OF TRANSPLANTATION : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF TRANSPLANTATION AND THE AMERICAN SOCIETY OF TRANSPLANT SURGEONS MAR 2006, vol. 6, no. 3, March 2006 (2006-03-01), pages 505 - 513, XP002467595, ISSN: 1600-6135 *
OGASAWARA KOUETSU ET AL: "NKG2D blockade prevents autoimmune diabetes in NOD mice", IMMUNITY, CELL PRESS, US, vol. 20, no. 6, June 2004 (2004-06-01), pages 757 - 767, XP002359222, ISSN: 1074-7613 *
VINCENTI F ET AL: "COSTIMULATION BLOCKADE WITH BELATACEPT IN RENAL TRANSPLANTATION", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, vol. 353, no. 8, 25 August 2005 (2005-08-25), pages 770 - 781, XP009070530, ISSN: 1533-4406 *
WEBER C J ET AL: "CTLA4-IG PROLONGS SURVIVAL OF MICROENCAPSULATED RABBIT ISLET XENOGRAFTS IN SPONTANEOUSLY DIABETIC NOD MICE", TRANSPLANTATION PROCEEDINGS, ORLANDO, FL, US, vol. 28, no. 2, April 1996 (1996-04-01), pages 821 - 823, XP008054845, ISSN: 0041-1345 *

Also Published As

Publication number Publication date
WO2008014035A2 (en) 2008-01-31

Similar Documents

Publication Publication Date Title
WO2005097160A3 (en) Modulation of nkg2d
WO2005074607A3 (en) Method of treating hemolytic disease
NO20091841L (en) Antibodies to Lymphotoxin-alpha
BRPI0506726A (en) specifically for m-csf and yours this
EP2500362A3 (en) Humanized antibodies against TL1A
TW200605907A (en) Preventing autoimmune disease
WO2007024921A3 (en) Combination therapies for inhibiting integrin-extracellular matrix interactions
WO2007098420A8 (en) Peptides that block the binding of igg to fcrn
MX2009004986A (en) Methods of treating hemolytic anemia.
WO2006118772A3 (en) Fcrn antibodies and uses thereof
MX2009004532A (en) Compositions and methods for binding sphingosine-1-phosphate.
UA104587C2 (en) Monoclonal antibody and a method of use thereof
WO2010142952A3 (en) Antibodies
WO2006012373A3 (en) Combination therapies of hmgb and complement inhibitors against inflammation
EP2330121A3 (en) Binding moieties based on Shark IgNAR domains
WO2006122257A3 (en) Nebulization of monoclonal antibodies for treating pulmonary diseases
NO20092743L (en) Antibodies to CD200R
WO2009097394A3 (en) Methods for modulating a population of myeloid-derived suppressor cells and uses thereof
WO2001098357A3 (en) Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations
GB0711327D0 (en) Diagnostic method
WO2007111938A3 (en) Inflammation-inhibitory serum factors and uses thereof
WO2007059300A3 (en) Anti-alk antagonist and agonist antibodies and uses thereof
WO2008008348A3 (en) Method and compositions for treating stroke with fever
WO2005079515A3 (en) Conformation specific antibodies
WO2006029220A3 (en) Combination therapy with anti-ctla4 and anti-4-1bb antibodies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07783369

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07783369

Country of ref document: EP

Kind code of ref document: A2